Daiwa Securities Group Inc. Boosts Holdings in Kenvue Inc. (NYSE:KVUE)

Daiwa Securities Group Inc. grew its stake in Kenvue Inc. (NYSE:KVUE) by 19.6% during the 4th quarter, Holdings Channel reports. The firm owned 166,852 shares of the company’s stock after purchasing an additional 27,380 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Kenvue were worth $3,593,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Clearstead Advisors LLC acquired a new stake in Kenvue in the 3rd quarter worth about $25,000. Planned Solutions Inc. acquired a new position in shares of Kenvue during the fourth quarter valued at approximately $27,000. AdvisorNet Financial Inc purchased a new position in shares of Kenvue in the third quarter valued at approximately $28,000. Global Retirement Partners LLC acquired a new stake in shares of Kenvue in the third quarter worth approximately $28,000. Finally, Venturi Wealth Management LLC acquired a new stake in shares of Kenvue in the third quarter worth approximately $28,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on KVUE. JPMorgan Chase & Co. reduced their price objective on Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 9th. William Blair started coverage on shares of Kenvue in a research report on Wednesday, April 3rd. They issued a “market perform” rating for the company. Sanford C. Bernstein started coverage on shares of Kenvue in a research report on Thursday, April 11th. They set an “underperform” rating and a $18.00 price target on the stock. Royal Bank of Canada dropped their price objective on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a research note on Friday, February 9th. Finally, The Goldman Sachs Group began coverage on shares of Kenvue in a research note on Friday, March 1st. They issued a “neutral” rating and a $20.00 target price on the stock. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $24.85.

Kenvue Stock Performance

Shares of NYSE KVUE opened at $19.58 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12. The company has a 50 day simple moving average of $19.84 and a 200-day simple moving average of $20.16. Kenvue Inc. has a 1 year low of $17.82 and a 1 year high of $27.80.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.03. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The company had revenue of $3.67 billion during the quarter, compared to analyst estimates of $3.78 billion. Kenvue’s revenue was down 2.7% compared to the same quarter last year. On average, analysts anticipate that Kenvue Inc. will post 1.15 EPS for the current year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 28th. Investors of record on Wednesday, February 14th were given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.09%. The ex-dividend date of this dividend was Tuesday, February 13th.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.